Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024
New data supports the value of the Oncotype DX Breast Recurrence Score® test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium® (SABCS®) from December 10-13 in San Antonio, Texas.
“Exact Sciences is committed to improving breast cancer care by providing actionable insights that support informed treatment decisions and help achieve the best outcomes for patients across all backgrounds,” said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology at Exact Sciences. “For 20 years, the Oncotype DX test has led the way in personalized treatment planning, and the new findings presented at SABCS reinforce its trusted role among clinicians, research institutions, and patients alike. With the addition of our OncoExTra® test and our anticipated molecular residual disease monitoring test, we’re equipping clinicians with innovative solutions to support patient needs throughout every stage of cancer care.”
In collaboration with leading breast cancer experts and research groups, Exact Sciences will share data highlighting how the Oncotype DX test helps guide effective chemotherapy use in everyday practice and clinical trials. New findings from Japan will show how the test supports decision making in breast cancer treatment and can help manage costs. Additionally, retrospective findings reveal African American women are more likely to have higher Recurrence Score® results than non-Hispanic White women, with similar survival outcomes. These insights emphasize how the Oncotype DX test can support more equitable breast cancer care across diverse populations and the need for further research to better understand factors behind racial disparities that currently exist.
Data presentations across Exact Sciences’ Precision Oncology portfolio include:
Title: (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response: Final survival results from the WSG ADAPT-HR+/HER2- chemotherapy-trial
Session: Late breaking oral presentation GS3-04. Friday, December 13, 9:00-11:45 AM CST; General Session 3, Hall 1
Title:Correlation between the Oncotype DX Recurrence Score® categories and progression-free survival of patients with primary metastatic estrogen-receptor positive and HER2-negative breast cancer
Session: Poster P4-12-01. Thursday, December 12, 5:30-7:00 PM CST; Poster Session 4, Halls 2 and 3
Title:The Oncotype DX® test to guide adjuvant chemotherapy treatment decisions for early node-negative HR+/HER2- breast cancer patients in Japan: a cost-effectiveness analysis
Session: Poster P4-11-07. December 12, 5:30-7:00 PM CST; Poster Session 4, Halls 2 and 3
Title:Comparative analysis of the Oncotype DX Breast Recurrence Score® assay for neoadjuvant letrozole/abemaciclib versus chemotherapy in Stage II-III, Ki67≥20%, HR+/HER2- breast cancer: insights from the GEICAM/CARABELA trial
Session: Poster P1-09-12. Wednesday, December 11, 12:30-2:00 PM CST; Poster Session 1, Halls 2 and 3
Title:Genomic risk score distribution and outcomes of patients with early-stage breast cancer diagnosed during pregnancy
Session: Poster P1-03-30. Wednesday, December 11, 12:30-2:00 PM CST; Poster Session 1, Halls 2 and 3
Title:Oncotype DX Breast Recurrence Score® distribution and prognostic value according to prior pregnancy status in young women with breast cancer
Session: Poster P1-01-23. Wednesday, December 11, 12:30 – 2:00 PM CST; Poster Session 1, Halls 2 and 3
Title:Oncotype DX assay association with breast cancer outcomes in different racial and ethnic groups: a retrospective analysis
Session: Poster P2-07-06. Wednesday, December 11, 5:30-7:00 PM CST; Poster Session 2, Halls 2 and 3
Title:Actionable gene alterations affecting the PI3K/AKT and MAPK signaling pathways in breast cancer
Session: Poster P4-03-25. Thursday, December 12, 5:30-7:00 PM CST; Poster Session 4, Halls 2 and 3
Title: Molecular landscape of breast cancer in pre- and postmenopausal women
Session: Poster P3-03-30. Thursday, December 12, 12:00-2:00 PM CST; Poster Session 3, Section Row 3 & Poster 30
Title: Economic analysis of germline genetic testing to assess for hereditary breast cancer: a systematic review
Session: Poster P4-04-14. Thursday, December 12, 5:30-7:00 PM CST; Poster Session 4, Halls 2 and 3
About Exact Sciences’ Precision Oncology portfolio
Exact Sciences’ Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX test is recognized as the standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today. The Riskguard® hereditary cancer test provides an individualized patient report that includes gene-specific and familial risks using a simple blood or saliva sample for 10 common cancers: colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney, and endocrine. Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine.
To learn more, visit precisiononcology.exactsciences.com.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
NOTE: Oncotype, Oncotype DX Breast Recurrence Score, Breast Recurrence Score, Recurrence Score, and OncoExTra are registered trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences. Exact Sciences, Cologuard and Riskguard are registered trademarks of Exact Sciences Corporation. Cologuard, Riskguard, and OncoExTra are only available in the United States.
Forward-Looking Statement
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated.
Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements regarding our expectations for the commercialization of the Cologuard Plus test and the performance of the Cologuard Plus test in a commercial setting. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125084124/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
28th World Investment Conference Kicks Off in Riyadh, Uniting Global Leaders in Investment for Sustainable Growth25.11.2024 23:07:00 CET | Press release
Inaugural sessions emphasize digital transformation, sustainability, and Saudi Arabia’s leadership in global investment opportunities Invest Saudi and The World Association of Investment Promotion Agencies (WAIPA) officially launched the 28th World Investment Conference (WIC) today in Riyadh. With an overarching theme of ‘Harnessing Digital Transformation and Sustainable Growth: Scaling Investment Opportunities’, the first day brought together more than 2,000 attendees from 130 countries, including 30 ministers, to explore key strategies for overcoming global investment challenges and unlocking opportunities for the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241125177448/en/ Saudi Minister of Investment, H.E. Khalid A. Al-Falih, addresses delegates at the 28th World Investment Conference in Riyadh, Saudi Arabia. (Photo: AETOSWire) H.E. Khalid A. Al-Falih, Saudi Minister of Investment, opened the event with an ins
NIKE, Inc. Appoints Treasure Heinle as Executive Vice President and Chief Human Resources Officer25.11.2024 22:15:00 CET | Press release
Monique Matheson, NIKE’s long-tenured Chief HR Officer, will retire after 26 years with the company NIKE, Inc. (NYSE: NKE) today announced a change to its Senior Leadership Team (SLT). Treasure Heinle, Chief Talent Officer, will become the company’s new Executive Vice President and Chief Human Resources Officer (CHRO). In her new role, Heinle will be responsible for leading the global HR function and managing NIKE’s People vision and strategy. She succeeds Monique Matheson who has decided to retire from NIKE after 26 years with the company. This leadership change is effective January 6, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241125954625/en/ Treasure Heinle (Photo: Business Wire) “Treasure is a well-rounded leader who, during her extensive career, has successfully worked across all aspects of the HR function,” said Elliott Hill, President & CEO, NIKE, Inc. “She has a strong record of bringing the best to NIKE,
History-Making Beechcraft T-6C Texan II Sale Supports the U.S.-Vietnam Comprehensive Strategic Partnership, Advances U.S. Interests in the Indo-Pacific Region25.11.2024 19:17:00 CET | Press release
Textron Aviation Defense today announced the arrival of five Beechcraft T-6C Texan II Integrated Training System (ITS) aircraft in support of the Vietnam Air Defense Air Force (ADAF) pilot training program at Phan Thiet Airbase. The historic delivery of the first of 12 T-6C Texan II ITS aircraft highlights the on-time fulfillment of the inaugural Foreign Military Sales (FMS) program established between the U.S. Air Force (USAF) and the ADAF. Contracted in August 2022, the full fleet of 12 T-6C aircraft is anticipated to be delivered by mid-2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241119463998/en/ Textron Aviation | Delivery of Cutting-Edge Training Aircraft Expands U.S.-Vietnam Security Cooperation (Photo: Business Wire) The Beechcraft T-6C Texan II is designed and manufactured by Textron Aviation Defense LLC, a wholly owned subsidiary of Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “It’s an honor to
ProAmpac’s Fiber-Based HandRap™ Packaging Earns Top Honors at UK Packaging Awards25.11.2024 17:18:00 CET | Press release
ProAmpac, a leader in flexible packaging and material science, is thrilled to announce its win at the prestigious 2024 UK Packaging Awards. ProAmpac received the Cartonboard Pack of the Year award for the innovative Pret Hong Kong RecycAll HandRap™ range. In addition to this remarkable achievement, ProAmpac was also honored with five other packaging award nominations, further solidifying its position as a trailblazer in the packaging industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241125232229/en/ HandRap RecycAll (Photo: Business Wire) Held at the iconic Grosvenor House Hotel in London, the UK Packaging Awards celebrates the best in packaging innovation. Industry leaders gather to honor the most impactful solutions of the year. "We are honored to receive this prestigious recognition from the UK Packaging Awards for our Pret Hong Kong RecycAll HandRap range,” shared Graham Williams, senior vice president, EU fiber d
Nexo Introduces Industry-First Personal USD Accounts25.11.2024 16:10:00 CET | Press release
Setting a new industry standard, Nexo is the first to offer users USD, EUR, and GBP accounts in their names, simplifying bank transactions with a unified view and streamlined tracking. Nexo, a premier digital assets wealth platform, announces the launch of the industry's first Personal USD Accounts, bringing clients in over 150 countries a seamless and familiar way to access USD bank transfers directly to and from their accounts, all in their name. Nexo now uniquely offers USD, EUR, and GBP accounts in clients’ names providing personal multi-currency management in one platform — a service unmatched in the industry. This milestone marks a pivotal step in Nexo’s long-term roadmap in introducing innovative ways for its clients to grow, manage, and spend their digital asset wealth while solidifying the company’s position as a leader in providing a seamless and intuitive experience. With the introduction of Personal USD Accounts, Nexo empowers clients to top up and withdraw USD through bank
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom